Program

Speaker

Chairs

Patient representative

TBD

Suzan Al-Gburi

Bjoern Bachmann

Paul Broeckelmann

Margarita Calonge

Prajakta Dandekar

Cintia de Paiva

Tina Dietrich-Ntoukas

Jörg Distler

Najla El-Jurdi

Michael Hallek

Tarik Isik

Sandeep Jain

Hamid Kashkar

Philip Keye

Thomas Krieg

Florian Kron

Stepanie Lee

Arghavan Lotfi

Teresa Magone de Quadros Costa

Leonie Mengesha

Jana Naetlitz

Sridevi Nair

Frauke Naumann-Winter

Ian Odell

Yoko Ogawa

Steven Pflugfelder

Christof Scheid

Helene Schoemans

Ajay Sharma

Avik Shome

Georg Star

Georg Stary

Michael E. Stern

Philipp Steven

Johanna Strobl

Sarah Sunshine

Christoph Ullmer

Murugesan Vanathi

Johannes Waldschmidt

Daniela Weber

Daniel Wolff

Robert Zeiser

Program

download as PDF

08:45 AM - 09:00 AM 15min

08:45 AM - 09:00 AM

Opening remarks

Philipp Steven

09:00 AM - 10:10 AM 1h 10min

Session 1

Daniel Wolff, Avik Shome

Progress in understanding ocular GVHD pathogenesis

09:00 AM - 09:20 AM

Role of NFkB in ocular GVHD

Avik Shome
09:20 AM - 09:40 AM

Fibroblast-Immune Cell Cross Talk in oGVHD

Ajay Sharma
09:40 AM - 10:00 AM

Immune dysregulation and tissue remodeling in ocular GVHD

Yoko Ogawa
10:00 AM - 10:10 AM

Discussion

10:10 AM - 10:30 AM 20min

Coffee break

10:30 AM - 12:00 PM 1h 30min

Session 2

Yoko Ogawa, Sandeep Jain

Novel targets and therapies for ocular GVHD

10:30 AM - 10:50 AM

Window of opportunity

Sandeep Jain
10:50 AM - 11:10 AM

Non-pharmacological therapies for ocular GVHD

Margarita Calonge
11:10 AM - 11:30 AM

Drug-repurposing in ocular GVHD

Murugesan Vanathi
11:30 AM - 11:50 AM

From Clinical Phenotype to transcriptional Targets: A Drug Discovery Platform applicable for oGVHD

Christoph Ullmer
11:50 AM - 12:00 PM

Discussion

12:00 PM - 01:00 PM 1h

Group Photo & Lunch Break

01:00 PM - 01:45 PM 45min

Keynote

01:00 PM - 01:05 PM

Introduction

Philipp Steven
01:05 PM - 01:45 PM

Targeting new treatments to specific organs

Stepanie Lee

01:45 PM - 03:00 PM 1h 15min

Session 3

Stepanie Lee, Leonie Mengesha

Early detection and/or prophylaxis of ocular GVHD

01:45 PM - 02:05 PM

Diagnosing ocular GVHD earlier: Diagnostic Challenges and Opportunities

Sarah Sunshine
02:05 PM - 02:25 PM

The BEACON study

Leonie Mengesha
02:25 PM - 02:45 PM

Navigating the dilemma of systemic therapy for organ-specific GVHD

Daniel Wolff
02:45 PM - 03:00 PM

Discussion

03:00 PM - 03:30 PM 30min

Coffee break

03:30 PM - 04:40 PM 1h 10min

Session 4

Tina Dietrich-Ntoukas, Bjoern Bachmann

Surgery, advanced management and prevention of complications of ocular GVHD

03:30 PM - 03:50 PM

To dos and not to dos in catastrophic ocular GVHD

Tina Dietrich-Ntoukas
03:50 PM - 04:10 PM

Scleral lenses in ocular GVHD

Philip Keye
04:10 PM - 04:30 PM

Specialized-care program in ocular GVHD

Tarik Isik
04:30 PM - 04:40 PM

Discussion

04:40 PM - 05:15 PM 35min

ePoster Session

Philipp Steven

04:40 PM - 04:50 PM

Adjunct Therapy with Topical Recombinant Deoxyribonuclease (DNase) in Dry Eye Disease

Sridevi Nair
04:50 PM - 05:00 PM

Selecting between autologous serum, punctual cautery, and dacryocystectomy in severe ocular GVHD: Clinical outcomes and decision-making criteria

Prajakta Dandekar
05:00 PM - 05:10 PM

Metabolic Alterations in Murine Skin Following induced Graft-versus-Host Disease

Arghavan Lotfi
05:10 PM - 05:15 PM

Discussion

Looks like there are no sessions today for the selected program.

09:00 AM - 09:15 AM 15min

09:00 AM - 09:15 AM

Opening remarks

Christof Scheid

09:15 AM - 10:00 AM 45min

Whitepaper & Roadmap

09:15 AM - 09:20 AM

Introduction

Philipp Steven
09:20 AM - 10:00 AM

Discussion

10:00 AM - 11:30 AM 1h 30min

Session 5

Robert Zeiser, Michael E. Stern

Interplay between systemic and organ-specific GVHD

10:00 AM - 10:20 AM

Manifestations of systemic immunity in the eye

Michael E. Stern
10:20 AM - 10:40 AM

Role of monocytes in innate immunity of the ocular surface

Steven Pflugfelder
10:40 AM - 11:00 AM

Current understanding of the impact of intestinal microbiome on HSCT alloreactive phenomena and outcome

Daniela Weber
11:00 AM - 11:20 AM

Cell death, inflammation and disease

Hamid Kashkar
11:20 AM - 11:30 AM

Discussion

11:30 AM - 11:45 AM 15min

Coffee break

11:45 AM - 01:15 PM 1h 30min

Session 6

Jana Naetlitz, Thomas Krieg

Skin GVHD

11:45 AM - 12:05 PM

Pathophysiology of fibrotic remodeling in cutaneous cGvHD

Jörg Distler
12:05 PM - 12:25 PM

Under the skin: the pathophysiology of cutaneous graft-versus-host disease

Johanna Strobl
12:25 PM - 12:45 PM

Bicentric data of dermatological care for GvHD patients

Suzan Al-Gburi
12:45 PM - 01:05 PM

Metabolic kinetics in cutaneous GvHD development

Jana Naetlitz
01:05 PM - 01:15 PM

Discussion

01:15 PM - 02:15 PM 1h

Lunch break

02:15 PM - 03:30 PM 1h 15min

Session 7

Philipp Steven, Florian Kron

Orphan drug approvals and the patient perspective

02:15 PM - 02:35 PM

The ocular GVHD patient

Patient representative
02:35 PM - 02:55 PM

eGVHD App and novel developments

Helene Schoemans
02:55 PM - 03:15 PM

Health economics in GVHD

Florian Kron
03:15 PM - 03:30 PM

Discussion

03:30 PM - 04:00 PM 30min

Coffee break

04:00 PM - 05:30 PM 1h 30min

Session 8

Christof Scheid, Paul Broeckelmann

Ocular toxicities beyond GVHD – Bispecifics, check-point inhibitors, ADCs and CAR-T

04:00 PM - 04:20 PM

iTox - Checkpoint inhibitors

Paul Broeckelmann
04:20 PM - 04:40 PM

Antibody Drug-Conjugates

Johannes Waldschmidt
04:40 PM - 05:00 PM

Bispecifics

Christof Scheid
05:00 PM - 05:20 PM

CAR-T

Christof Scheid
05:20 PM - 05:30 PM

Discussion

05:30 PM - 06:15 PM 45min

Wrap up

05:30 PM - 06:00 PM

What’s new, what have we learned?

Chairs
06:00 PM - 06:15 PM

Farewell comments

Philipp Steven, Christof Scheid

Looks like there are no sessions today for the selected program.

Day 1

03/19/2026

Day 2

03/20/2026